Xing-Guo Li^1,2,3,#, Lu-Kai Wang^4,#, Fu-Ming Tsai⁵, Hsueh-Chun Wang^1,*

BIOCELL, Vol.50, No.6, 2026, DOI:10.32604/biocell.2026.075492 - 09 June 2026

Abstract Itaconate, produced by aconitate decarboxylase 1 (ACOD1, also known as IRG1), acts as a key immunometabolite that inhibits succinate dehydrogenase (SDH) and can engage reduction-oxidation (redox)-sensitive signaling programs. This review summarizes the emerging, context-dependent roles of the ACOD1-itaconate axis in cancer, while critically distinguishing between the effects of endogenous itaconate and its cell-permeable derivatives. In tumor cells, endogenous ACOD1 expression or uptake via solute carrier family 13 member 3 (SLC13A3) alters oxidative phosphorylation and glycolysis. In the tumor microenvironment, myeloid-derived itaconate contributes to immune tolerance by reducing dendritic-cell cross-priming and limiting CD8⁺ T-cell metabolic activity. Moreover, More >

Shail Rakesh Modi, Terrick Andey^*, George Acquaah-Mensah^*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.070793 - 19 January 2026

Abstract Objectives: The current treatment options and therapeutic targets for triple-negative breast cancer (TNBC), an aggressive subtype of breast cancer (BrCA), are limited. This study aimed to identify novel biomarkers and transcriptional regulatory networks (TRN) inherent in TNBC samples. Methods: We analyzed pan-cancer BrCA datasets from The Cancer Genome Atlas (TCGA) to compare triple-positive breast cancer (TPBC) with TNBC. TRN algorithms and virtual inference of protein-enriched regulon (VIPER) were used to identify master regulators and their target genes. Utilizing TNBC cells (MDA-MB-231 and MDA-MB-468), we validated the relationship of nuclear factor erythroid 2-like 3 (NFE2L3) and… More > Graphic Abstract

JIE DUAN, AIDONG GU^*, WEI CHEN, CHANGHAO CHEN, FANGNAN SONG, FAXI CHEN, FANGFANG JIANG, HUIWEN XING

BIOCELL, Vol.47, No.12, pp. 2609-2615, 2023, DOI:10.32604/biocell.2023.042472 - 27 December 2023

Abstract Objective: This study aims to analyze the clinical significance and mechanism of nuclear factor erythroid 2-related factor 2 (NRF2) and glutathione peroxidase 4 (GPX4) in primary hepatic carcinoma (PHC). Methods: The expression of NRF2 and GPX4 in peripheral blood of patients with PHC was determined to analyze the diagnostic value of the two combined for PHC. The prognostic significance of NRF2 and GPX4 was evaluated by 3-year follow-up. Human liver epithelial cells THLE-2 and human hepatocellular carcinoma cells HepG2 were purchased, and the expression of NRF2 and GPX4 in the cells was determined. NRF2 and GPX4… More > Graphic Abstract